Incode First to Achieve iBeta’s Highest Level of Independent Identity Security Testing on Both iOS and Android With 0% Error Rate
2.3.2026 16:00:00 EET | Business Wire | Press release
Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation Attack Detection (PAD) conformance under ISO/IEC 30107-3.
"We are the first company to independently achieve iBeta Level 3 conformance on both iOS and Android – with zero errors and without adding friction to users," said Ricardo Amper, Founder & CEO at Incode. "That combination matters. It proves we can meet the highest bar for liveness assurance while keeping onboarding fast and easy, even in regulated and high-risk environments."
Face liveness technology is used in digital onboarding and authentication to confirm a real, live person is present during a selfie capture – not a printed photo, video replay, mask, or other spoofing attempt. It enables organizations to defend remote identity verification flows against account takeovers, synthetic identity fraud, and impersonation scams.
Incode’s solution is passive and completes verification with a single selfie, reducing friction compared to challenge-based experiences while maintaining strong resistance to sophisticated presentation attacks.
This level of assurance matters most at scale – where identity decisions impact conversions, fraud losses, and customer trust across millions of users. Incode operates at that scale, powering trusted experiences for 8 of the top 10 U.S. banks, 8 of the top 9 telecom companies, the top 3 global neobanks, and 4 of the top 5 marketplaces worldwide. To date, Incode has processed more than 7.1 billion trust checks.
From Level 1 to Level 3. A clear progression
In 2019, Incode launched a passive liveness model designed to detect common 2D presentation attacks including printed photos and replay attacks. That release led to Incode becoming the first vendor to pass iBeta Level 1 using a passive liveness approach.
By 2022, Incode expanded its defenses to address advanced 3D mask attacks while continuing to strengthen 2D detection. These improvements enabled Incode to pass iBeta PAD Level 2 testing in early 2023.
In 2026, Incode achieved iBeta PAD Level 3 conformance on both iOS and Android, with a perfect score.
Independent validation at the highest PAD level
"iBeta Level 3 is designed to simulate well-resourced attackers using hyper-realistic masks and specialized fabrication techniques intended to challenge modern biometric systems," said Evan Call, Business Development Manager and Director of Biometrics Sales and Marketing at iBeta Quality Assurance. "Incode’s results demonstrate conformance at Level 3 on both iOS and Android, with 0% APCER and 0% BPCER reported during testing."
APCER (Attack Presentation Classification Error Rate) captures whether spoofing attempts are incorrectly accepted, while BPCER (Bona Fide Presentation Classification Error Rate) captures whether legitimate users are incorrectly rejected. Incode reported 0% on both metrics – no presentation attacks were accepted, and no legitimate users were rejected during the evaluation.
Incode’s verification is completed from a single selfie capture, with no challenge prompts (such as turning head, or smiling), helping reduce friction while maintaining strong resistance to sophisticated presentation attacks.
Why this matters now
Digital onboarding has become the primary gateway to financial services, marketplaces, and government platforms - making identity assurance a critical control point for both security and growth.
Organizations face mounting pressure to reduce fraud losses while minimizing false rejections that disrupt user experience and impact revenue. But as attackers become more sophisticated, it’s increasingly difficult for teams to evaluate liveness vendors under the most demanding real-world conditions, especially across devices, environments, and advanced presentation attacks. Independent testing at the highest available PAD level helps buyers cut through claims and identify the solutions that hold up when stakes are highest.
This milestone reflects Incode’s continued commitment to proprietary innovation and world-class engineering talent globally.
About Incode
Incode is the global leader in trust and identity. Incode’s state-of-the-art AI platform offers a highly secure and seamless AI-based experience that eliminates fraud and drives growth for businesses. With its mission to power a world of trust, Incode works with many of the world’s largest banks, fintechs, telcos, governments, and marketplaces. Incode is headquartered in San Francisco and has offices in Europe and Latin America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302578536/en/
Contacts
Seki Berg, incode@sourcecodecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom